La gestion inclut un suivi médical régulier et des traitements adaptés aux complications.
GestionSuivi médicalComplications
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque du TEV ?
Les facteurs incluent l'immobilisation, l'obésité, les antécédents familiaux et certaines maladies.
Facteurs de risqueObésitéAntécédents familiaux
#2
L'âge influence-t-il le risque de TEV ?
Oui, le risque de TEV augmente avec l'âge, surtout après 60 ans.
ÂgeRisqueThromboembolie veineuse
#3
Les femmes enceintes sont-elles à risque ?
Oui, la grossesse augmente le risque de TEV en raison des changements hormonaux et de la circulation.
GrossesseRisqueThromboembolie veineuse
#4
Les antécédents de TEV augmentent-ils le risque ?
Oui, avoir des antécédents de TEV augmente significativement le risque de récidive.
AntécédentsRisqueThromboembolie veineuse
#5
Le tabagisme est-il un facteur de risque ?
Oui, le tabagisme augmente le risque de formation de caillots sanguins.
TabagismeFacteurs de risqueThromboembolie veineuse
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Thromboembolisme veineux : Questions médicales les plus fréquentes",
"headline": "Thromboembolisme veineux : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Thromboembolisme veineux : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-21",
"dateModified": "2025-04-17",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Thromboembolisme veineux"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Thromboembolie",
"url": "https://questionsmedicales.fr/mesh/D013923",
"about": {
"@type": "MedicalCondition",
"name": "Thromboembolie",
"code": {
"@type": "MedicalCode",
"code": "D013923",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C14.907.355.590"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Thromboembolisme veineux",
"alternateName": "Venous Thromboembolism",
"code": {
"@type": "MedicalCode",
"code": "D054556",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Jean M Connors",
"url": "https://questionsmedicales.fr/author/Jean%20M%20Connors",
"affiliation": {
"@type": "Organization",
"name": "Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Francis Couturaud",
"url": "https://questionsmedicales.fr/author/Francis%20Couturaud",
"affiliation": {
"@type": "Organization",
"name": "CHU Brest, Département de Médecine Interne et Pneumologie, Brest, France; Univ_Brest, INSERM U1304-GETBO, CIC INSERM 1412, F29609 Brest; FCRIN INNOVTE network, Saint-Etienne, France. Electronic address: francis.couturaud@chu-brest.fr."
}
},
{
"@type": "Person",
"name": "Susan R Kahn",
"url": "https://questionsmedicales.fr/author/Susan%20R%20Kahn",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, McGill University, Montreal, QC, Canada; Division of Internal Medicine and Division of Clinical Epidemiology, Jewish General Hospital/Lady Davis Institute, Montreal, QC, Canada."
}
},
{
"@type": "Person",
"name": "Marc Blondon",
"url": "https://questionsmedicales.fr/author/Marc%20Blondon",
"affiliation": {
"@type": "Organization",
"name": "Service d'angiologie et d'hémostase, HUG, 1211 Genève 14, et Faculté de médecine, Université de Genève, 1211 Genève 4."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Interpreting the biological effects of protons as a function of physical quantity: linear energy transfer or microdosimetric lineal energy spectrum?",
"datePublished": "2024-10-24",
"url": "https://questionsmedicales.fr/article/39448656",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-73619-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Treatment-planning approaches to intensity modulated proton therapy and the impact on dose-weighted linear energy transfer.",
"datePublished": "2022-09-26",
"url": "https://questionsmedicales.fr/article/36161765",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/acm2.13782"
}
},
{
"@type": "ScholarlyArticle",
"name": "Calculating dose-averaged linear energy transfer in an analytical treatment planning system for carbon-ion radiotherapy.",
"datePublished": "2022-12-17",
"url": "https://questionsmedicales.fr/article/36527366",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/acm2.13866"
}
},
{
"@type": "ScholarlyArticle",
"name": "Radio-fluorogenic nanoclay gel dosimeters with reduced linear energy transfer dependence for carbon-ion beam radiotherapy.",
"datePublished": "2022-11-29",
"url": "https://questionsmedicales.fr/article/36335533",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/mp.16092"
}
},
{
"@type": "ScholarlyArticle",
"name": "Linear energy transfer (LET) distribution outside small radiotherapy field edges produced by 6 MV X-rays.",
"datePublished": "2023-12-06",
"url": "https://questionsmedicales.fr/article/38052891",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-44409-8"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies cardiovasculaires",
"item": "https://questionsmedicales.fr/mesh/D002318"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies vasculaires",
"item": "https://questionsmedicales.fr/mesh/D014652"
},
{
"@type": "ListItem",
"position": 4,
"name": "Embolie et thrombose",
"item": "https://questionsmedicales.fr/mesh/D016769"
},
{
"@type": "ListItem",
"position": 5,
"name": "Thromboembolie",
"item": "https://questionsmedicales.fr/mesh/D013923"
},
{
"@type": "ListItem",
"position": 6,
"name": "Thromboembolisme veineux",
"item": "https://questionsmedicales.fr/mesh/D054556"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Thromboembolisme veineux - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Thromboembolisme veineux",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Thromboembolisme veineux",
"description": "Comment diagnostiquer un thromboembolisme veineux ?\nQuels tests sont utilisés pour confirmer un TEV ?\nQuels signes cliniques indiquent un TEV ?\nLe scanner est-il utile pour le TEV ?\nComment évaluer le risque de TEV ?",
"url": "https://questionsmedicales.fr/mesh/D054556?mesh_terms=Linear+Energy+Transfer#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Thromboembolisme veineux",
"description": "Quels sont les symptômes d'un TEV ?\nComment se manifeste une embolie pulmonaire ?\nLe TEV peut-il être asymptomatique ?\nQuels signes alertent sur un TEV ?\nLes symptômes varient-ils selon l'emplacement ?",
"url": "https://questionsmedicales.fr/mesh/D054556?mesh_terms=Linear+Energy+Transfer#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Thromboembolisme veineux",
"description": "Comment prévenir le TEV ?\nLes bas de compression aident-ils ?\nQuand est-il crucial de prévenir le TEV ?\nLes voyages longs augmentent-ils le risque ?\nL'activité physique réduit-elle le risque ?",
"url": "https://questionsmedicales.fr/mesh/D054556?mesh_terms=Linear+Energy+Transfer#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Thromboembolisme veineux",
"description": "Quels traitements sont disponibles pour le TEV ?\nComment fonctionnent les anticoagulants ?\nQuand utiliser la thrombolyse ?\nQuels sont les effets secondaires des anticoagulants ?\nLe traitement préventif est-il nécessaire ?",
"url": "https://questionsmedicales.fr/mesh/D054556?mesh_terms=Linear+Energy+Transfer#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Thromboembolisme veineux",
"description": "Quelles sont les complications du TEV ?\nL'embolie pulmonaire est-elle grave ?\nQu'est-ce que le syndrome post-thrombotique ?\nLe TEV peut-il entraîner des problèmes cardiaques ?\nComment gérer les complications du TEV ?",
"url": "https://questionsmedicales.fr/mesh/D054556?mesh_terms=Linear+Energy+Transfer#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Thromboembolisme veineux",
"description": "Quels sont les principaux facteurs de risque du TEV ?\nL'âge influence-t-il le risque de TEV ?\nLes femmes enceintes sont-elles à risque ?\nLes antécédents de TEV augmentent-ils le risque ?\nLe tabagisme est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D054556?mesh_terms=Linear+Energy+Transfer#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un thromboembolisme veineux ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation clinique, l'échographie Doppler et les tests sanguins."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer un TEV ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'échographie, le D-dimère et parfois l'angiographie."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent un TEV ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent douleur, œdème, rougeur et chaleur dans la zone affectée."
}
},
{
"@type": "Question",
"name": "Le scanner est-il utile pour le TEV ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le scanner thoracique peut détecter une embolie pulmonaire associée."
}
},
{
"@type": "Question",
"name": "Comment évaluer le risque de TEV ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des scores comme le score de Wells aident à évaluer le risque de TEV."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'un TEV ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur, gonflement, chaleur et rougeur dans la jambe."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une embolie pulmonaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle se manifeste par une douleur thoracique, essoufflement et parfois toux avec sang."
}
},
{
"@type": "Question",
"name": "Le TEV peut-il être asymptomatique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains cas de TEV peuvent ne présenter aucun symptôme visible."
}
},
{
"@type": "Question",
"name": "Quels signes alertent sur un TEV ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un gonflement soudain d'une jambe et une douleur intense sont des signes d'alerte."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'emplacement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon que le caillot est dans une veine profonde ou pulmonaire."
}
},
{
"@type": "Question",
"name": "Comment prévenir le TEV ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut l'exercice régulier, l'hydratation et l'utilisation d'anticoagulants si nécessaire."
}
},
{
"@type": "Question",
"name": "Les bas de compression aident-ils ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les bas de compression aident à améliorer la circulation sanguine et à prévenir le TEV."
}
},
{
"@type": "Question",
"name": "Quand est-il crucial de prévenir le TEV ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Après une chirurgie ou lors d'une immobilisation prolongée, la prévention est cruciale."
}
},
{
"@type": "Question",
"name": "Les voyages longs augmentent-ils le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyages prolongés en position assise augmentent le risque de TEV."
}
},
{
"@type": "Question",
"name": "L'activité physique réduit-elle le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activité physique régulière aide à réduire le risque de formation de caillots."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour le TEV ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent les anticoagulants, la thrombolyse et parfois la chirurgie."
}
},
{
"@type": "Question",
"name": "Comment fonctionnent les anticoagulants ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils empêchent la formation de nouveaux caillots et aident à dissoudre les existants."
}
},
{
"@type": "Question",
"name": "Quand utiliser la thrombolyse ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thrombolyse est utilisée dans les cas graves d'embolie pulmonaire pour dissoudre rapidement le caillot."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des anticoagulants ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent des saignements, des ecchymoses et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Le traitement préventif est-il nécessaire ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chez les patients à risque, un traitement préventif est souvent recommandé."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications du TEV ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'embolie pulmonaire, l'insuffisance veineuse et le syndrome post-thrombotique."
}
},
{
"@type": "Question",
"name": "L'embolie pulmonaire est-elle grave ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'embolie pulmonaire peut être mortelle et nécessite une attention médicale immédiate."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que le syndrome post-thrombotique ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est une complication chronique du TEV, entraînant douleur et gonflement persistants."
}
},
{
"@type": "Question",
"name": "Le TEV peut-il entraîner des problèmes cardiaques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une embolie pulmonaire peut provoquer des problèmes cardiaques en surchargeant le cœur."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications du TEV ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut un suivi médical régulier et des traitements adaptés aux complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du TEV ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'immobilisation, l'obésité, les antécédents familiaux et certaines maladies."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de TEV ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de TEV augmente avec l'âge, surtout après 60 ans."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes sont-elles à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la grossesse augmente le risque de TEV en raison des changements hormonaux et de la circulation."
}
},
{
"@type": "Question",
"name": "Les antécédents de TEV augmentent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir des antécédents de TEV augmente significativement le risque de récidive."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de formation de caillots sanguins."
}
}
]
}
]
}
Department of Medicine, McGill University, Montreal, QC, Canada; Division of Internal Medicine and Division of Clinical Epidemiology, Jewish General Hospital/Lady Davis Institute, Montreal, QC, Canada.
The choice of appropriate physical quantities to characterize the biological effects of ionizing radiation has evolved over time coupled with advances in scientific understanding. The basic hypothesis...
We quantified the effect of various forward-based treatment-planning strategies in proton therapy on dose-weighted linear energy transfer (LETd). By maintaining the dosimetric quality at a clinically ...
Eight treatment-planning strategies that are achievable in commercial treatment-planning systems were applied on a cylindrical water phantom and four pediatric brain tumor cases. Each planning strateg...
In the phantom study, using a range shifter and altering the robust scenarios during optimization had the largest effect on the mean clinical target volume LETd, which was reduced from 4.5 to 3.9 keV/...
Changes in LETd from treatment-plan setup follow intuitive trends in a controlled phantom experiment. Anatomical and other patient-specific considerations, however, can preclude generalizable strategi...
Compelling evidence shows the association between the relative biological effectiveness (RBE) of carbon-ion radiotherapy (CIRT) and the dose averaged linear energy transfer (LETd). However, the abilit...
This study aims to develop a method of calculating the LETd of CIRT plans that could be robustly carried out in RayStation (V10B, Raysearch, Sweden)....
The calculation used the fragment spectra in RayStation for the CIRT treatment planning. The dose-weighted averaging procedure was supported by the microdosimetric kinetic model (MKM). The MKM-based p...
The differences in LETds of the monoenergetic beams between the new method and the traditional method were within 3% in the entrance and Bragg-peak regions. However, a larger difference was observed i...
The method presented herein reformulates the MKM dose engine in the RayStation TPS to inversely calculate LETds. The robustness and accuracy were demonstrated....
The precise assessment of the dose distribution of high linear energy transfer (LET) radiation remains a challenge, because the signal of most dosimeters will be saturated due to the high ionization d...
Nanoclay radio-fluorogenic gel (NC-RFG) dosimeters were prepared, typically containing 100 μM dihydrorhodamine 123 (DHR123) and 2.0 wt% nanoclay together with catalytic additives promoting Fenton or F...
An NC-RFG dosimeter capable of generating a fluorescence intensity distribution reflecting the carbon-ion beam dose profile was obtained. It was clarified that the reduction of the unfavorable LET dep...
This technique allows the first-ever evaluation of the depth-dose profile of a carbon-ion beam at typical therapeutic levels of several Gy without LET effect....
In modern radiotherapy with photons, the absorbed dose outside the radiation field is generally investigated. But it is well known that the biological damage depends not only on the absorbed dose but ...
The use of radiation with low and high linear energy transfer (LET) in the same treatment regimen is promising in terms of increasing the efficiency and reducing the severity of radiation complication...
Different alpha exposure setups are often used to study the relation between biological responses and LET. This study aimed to estimate the dose heterogeneity and uncertainty in four exposure setups u...
Geant4 was used to estimate the dose distributions in cells grown on a disk exposed to alpha particles penetrating from above and below. The latter setup was simulated without and with a collimator. P...
The LET distributions obtained for simulated setups excluding the collimator were wide and non-Gaussian. Using a collimator resulted in a Gaussian LET distribution, but strongly reduced dose rate and ...
The interpretation of results from radiobiological experiments with alpha particles should always cover the characteristics of the experimental setup, which can be done precisely with computational me...
The correlation between dose-averaged linear energy transfer (LETd) and its therapeutic or adverse effects, especially in carbon-ion radiotherapy (CIRT), remains controversial. This study aimed to inv...
Among patients who underwent CIRT for uterine carcinoma, 101 who were followed up for > 6 months without any other therapy were retrospectively analyzed. The sacrum insufficiency fractures (SIFs) were...
At the last follow-up, 19 patients developed SIFs. Receiver operating characteristic curve analysis revealed that the sacrum D50% RBE-weighted dose was a valuable predictor of SIF. Univariate analyses...
The sacrum D50% RBE-weighted dose was identified as a risk factor for SIF. Additionally, neither LETd nor physical dose parameters were associated with SIF prediction....
The increasing number of studies dealing with linear energy transfer (LET)-based evaluation and optimization in the field of carbon ion radiotherapy (CIRT) indicates the rising demand for LET implemen...
This in silico study was conducted to benchmark the following two LET-related functionalities in a commercial TPS against Monte Carlo simulations: (1) dose averaged LET (LET...
The LET...
For all setups (homogeneous and heterogeneous), the mean absolute (and relative) LET...
No computation error was found in the tested functionalities except for LET...
A fixed relative biological effectiveness (RBE) of 1.1 (RBE...
36 patients treated with passive scattering proton therapy were selected for a case-control study from a cohort of 954 pediatric brain tumor patients. Nine children with symptomatic brainstem toxicity...
LET...
Trends towards higher LET...